Here, we reposition FLT3 as a critical determinant of CML progression via FLT3-JAK-STAT3-TAZ-TEAD-CD36 signaling pathway that promotes TKI resistance and predicts worse prognosis in BP-CML patients. This evidence concerns the gene STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive.